SUN PHARMA ADVANCED RESEARCH COMPANY
|
SUN PHARMA ADVANCED RESEARCH COMPANY Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 47.86 | -10.55 | -11.93 | -6.86 |
| CEPS(Rs) | 48.17 | -10.17 | -11.55 | -6.50 |
| DPS(Rs) | - | - | - | - |
| Book NAV/Share(Rs) | 41.25 | -6.68 | 3.88 | 15.80 |
| Tax Rate(%) | -0.01 | 0.08 | -0.10 | - |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 85.08 | -450.27 | -532.26 | -89.65 |
| EBIT Margin(%) | 84.46 | -465.04 | -509.81 | -90.02 |
| Pre Tax Margin(%) | 82.64 | -477.64 | -512.05 | -93.22 |
| PAT Margin (%) | 82.65 | -477.26 | -512.56 | -93.22 |
| Cash Profit Margin (%) | 83.20 | -459.99 | -496.00 | -88.29 |
| Performance Ratios | ||||
| ROA(%) | 124.17 | -80.88 | -57.63 | -26.81 |
| ROE(%) | 276.89 | - | -121.28 | -43.41 |
| ROCE(%) | 163.94 | -311.92 | -112.35 | -41.91 |
| Asset Turnover(x) | 1.50 | 0.17 | 0.11 | 0.29 |
| Sales/Fixed Asset(x) | 12.44 | 0.46 | 0.50 | 1.63 |
| Working Capital/Sales(x) | 1.70 | -0.21 | 17.46 | 0.87 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.08 | 2.20 | 2.01 | 0.61 |
| Receivable days | 2.36 | 80.33 | 116.55 | 50.01 |
| Inventory Days | - | - | - | - |
| Payable days | - | - | - | - |
| Valuation Parameters | ||||
| PER(x) | 2.39 | - | - | - |
| PCE(x) | 2.38 | -14.55 | -32.04 | -27.62 |
| Price/Book(x) | 2.78 | -22.14 | 95.47 | 11.36 |
| Yield(%) | - | - | - | - |
| EV/Net Sales(x) | 2.27 | 70.50 | 157.49 | 23.92 |
| EV/Core EBITDA(x) | 2.66 | -15.74 | -31.93 | -28.11 |
| EV/EBIT(x) | 2.69 | -15.16 | -30.89 | -26.57 |
| EV/CE(x) | 2.26 | 122.69 | 68.87 | 11.14 |
| M Cap / Sales | 1.98 | 66.93 | 158.92 | 24.39 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 2,518.47 | -5.00 | -68.36 | - |
| Core EBITDA Growth(%) | 600.93 | 13.76 | -83.40 | - |
| EBIT Growth(%) | 575.56 | 13.34 | -79.18 | - |
| PAT Growth(%) | 553.48 | 11.55 | -73.96 | - |
| EPS Growth(%) | 553.48 | 11.55 | -73.96 | - |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.42 | -1.19 | 0.37 | - |
| Current Ratio(x) | 2.47 | 0.07 | 1.02 | 2.54 |
| Quick Ratio(x) | 2.47 | 0.07 | 1.02 | 2.54 |
| Interest Cover(x) | 46.50 | -36.92 | -227.27 | -28.15 |
| Total Debt/Mcap(x) | 0.15 | 0.05 | - | - |
Compare Financial Ratios of peers of SUN PHARMA ADVANCED RESEARCH COMPANY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SUN PHARMA ADVANCED RESEARCH COMPANY | ₹7,022.2 Cr | -4.9% | -4.7% | 33% | Stock Analytics | |
| PRIME FOCUS | ₹22,448.3 Cr | 1.7% | 35% | 67% | Stock Analytics | |
| SAGILITY | ₹18,940.7 Cr | -2.1% | 1% | -8.1% | Stock Analytics | |
| SYNGENE INTERNATIONAL | ₹16,413.2 Cr | -2.6% | -8.2% | -39.8% | Stock Analytics | |
| INTERNATIONAL GEMOLOGICAL INSTITUTE | ₹14,639.4 Cr | -0.9% | -3.8% | -11.6% | Stock Analytics | |
| INDEGENE | ₹11,870.4 Cr | -3.2% | -6.5% | -15.5% | Stock Analytics | |
SUN PHARMA ADVANCED RESEARCH COMPANY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUN PHARMA ADVANCED RESEARCH COMPANY | -4.9% |
-4.7% |
33% |
| SENSEX | -2.7% |
-0.2% |
-8% |
You may also like the below Video Courses
